Vertex Pharmaceuticals Acquires ViaCyte for $320M

Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals

September 1, 2026

Pharmaceuticals

Vertex Pharmaceuticals Incorporated completed its acquisition of Crinetics Pharmaceuticals, Inc. on September 1, 2026, in a transaction valued at approximately $10 billion in equity value. The acquisition adds PALSONIFY, atumelnant and other pipeline programs, establishing rare endocrine diseases as a new growth area for Vertex.

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B

July 5, 2026

Pharmaceuticals

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for total equity value of about $10 billion ($8.8 billion net of estimated cash acquired). The deal—priced at $85 per share—was announced as a definitive agreement and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.

Incyte Acquires Vega Therapeutics to Expand Hematology Portfolio in Bleeding Disorders

June 8, 2026

Biotechnology

Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with up to $750 million in additional milestone payments for total potential consideration of up to $2.0 billion. The deal is intended to add Vega’s Phase 3 monoclonal antibody candidate VGA039 for von Willebrand disease to Incyte’s hematology portfolio.

BioIVT Acquires BeCytes Biotechnologies

November 4, 2025

Biotechnology

BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.